	US 12,146,185 B2
	Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
Mihael H. Polymeropoulos, Potomac, MD (US); and Sandra Smieszek, Cleveland, OH (US)
Assigned to Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed by Vanda Pharmaceuticals Inc., Washington, DC (US)
Filed on Nov. 29, 2021, as Appl. No. 17/536,306.
Application 17/536,306 is a continuation of application No. 16/542,575, filed on Aug. 16, 2019, granted, now 11,214,827.
Claims priority of provisional application 62/725,016, filed on Aug. 30, 2018.
Prior Publication US 2022/0081710 A1, Mar. 17, 2022
Int. Cl. C12Q 1/6827 (2018.01); G16H 50/30 (2018.01)

CPC C12Q 1/6827 (2013.01) [G16H 50/30 (2018.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01)]

13 Claims

1. In a method consisting of administering to a patient suffering from bipolar disorder an amount of a compound selected from iloperidone, a metabolite of iloperidone, or a pharmaceutically acceptable salt of iloperidone or the metabolite thereof, effective to treat a symptom of the bipolar disorder, the improvement comprising:

selecting said patient for treatment based upon a determination that said patient's genotype is selected from the group consisting of : rs2299503-AA, rs13222700-TT, rs11763603-CC, rs7049108-GG, rs579298-TT, rs11176436-TT, and rs17109739-CC.